Objective:To investigate the clinical efficacy and safety of amlodipine besylate and benazepril hydrochloride tablets (II) in the treatment of primary hypertension.Methods:A total of 280 patients with primary hypertension who were treated at Shougang Shuigang Hospital between June 2022 and June 2023 were selected as study subjects. A clinical case-control study was conducted, and the RAND function method was utilized to randomly allocate the subjects into four groups, each receiving a different treatment: amlodipine besylate group (Group A, n = 70), benazepril hydrochloride group (Group B, n = 70), compound formulation amlodipine besylate and benazepril hydrochloride tablets group (Group C, n = 71), and amlodipine besylate plus benazepril hydrochloride group (Group D, n = 69). Relevant therapeutic indicators (blood pressure compliance rate, changes in blood pressure values) and safety indicators (adverse reactions, medication adherence) were observed. Results:The blood pressure compliance rates of Group C and Group D were 91.5% (65/71) and 89.9% (62/69), respectively. There was no statistically significant difference between the two groups ( χ2 = 1.24, P = 0.143), but both were higher than the rates of 77.1% (54/70) and 74.3% (52/70) in Group A and Group B, respectively ( χ2 = 5.68, 4.86, P = 0.004, 0.012). Before treatment, there was no statistically significant difference in systolic and diastolic blood pressure among the four groups of patients (all P > 0.05). After treatment, there was a statistically significant decrease in both systolic and diastolic blood pressure among the four groups compared with their pre-treatment levels (all P < 0.05). Specifically, Group C and Group D exhibited significant reductions in blood pressure following treatment ( t = 4.35, 5.12, 7.25, 5.86, all P < 0.05). Meanwhile, there was no statistically significant difference in systolic blood pressure between Group C and Group D after treatment ( P > 0.05), while diastolic blood pressure was lower in Group C than Group D after treatment ( t = 6.01, P < 0.05). There was a significant downward trend observed in total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels (all P < 0.05). Notably, Group B and Group D reported higher incidences of dry cough, with 15 and 10 cases, respectively, compared with Group A and Group C, which had 1 and 3 cases, respectively. These differences were statistically significant ( χ2 = 4.25, 5.04, both P < 0.05). Furthermore, the treatment compliance rates for Group A, Group B, and Group C were 72.9% (51/70), 71.4% (50/70), and 74.6% (53/71), respectively, all exceeding the 46.4% (32/69) compliance rate of Group D. These differences were also statistically significant ( χ2 = 4.68, 5.24, 4.98, all P < 0.05). Conclusion:The clinical efficacy and safety of the compound formulation amlodipine besylate and benazepril hydrochloride tablets (II) in the treatment of primary hypertension are superior to those of single tablets and combination therapy.

Objective:To investigate the influence of serum uric acid level on the pregnancy outcome of frozen-thawed embryo transfer (FET).Methods:This study was a retrospective cohort study. Patients were recruited underwent the first FET cycles at the Reproductive Medicine Center of Affiliated Hospital of Nantong University from January 2017 to June 2022. According to uric acid >340 μmol/L or not, the patients were divided into high uric acid group ( n=157) and control group ( n=899). Propensity score matching (PSM) and multivariate logistic regression analysis were conducted to screen the risk factors for adverse pregnancy outcomes. Results:Patients in high uric acid group had a higher proportion of overweight [60.5% (95/157)], higher level of anti-Müllerian hormone [4.59 (3.23, 6.32) μg/L] and antral follicle count [21 (15, 28)] compared with control group [13.2% (119/899), P<0.001; 4.46 (2.51, 5.27) μg/L, P=0.024; 19 (12, 25), P=0.003], and lower levels of basic follicle-stimulating hormone [(6.73±2.04) U/L] and estradiol on transformation day [232.97 (147.13, 358.40) pmol/L] compared with control group [(7.42±2.29) U/L, P<0.001; 285.80 (189.11, 393.52) pmol/L, P=0.001]. The abortion rate was higher [43.7% (38/87)] and the live birth rate was lower [31.2% (49/157)] in high uric acid group than in control group [23.6% (120/509), P<0.001; 43.3% (389/899), P=0.005]. After PSM, the abortion rate was significantly higher in high uric acid group as far [43.7% (38/87)] than in control group [23.0% (17/74), P=0.006], and high uric acid greatly increased the abortion rate in FET patients before and after PSM (before PSM: OR=2.193, 95% CI: 1.301-3.697, P=0.003; after PSM: OR=3.482, 95% CI: 1.620-7.483, P=0.001). Conclusion:High level of uric acid before the pregnancy is an important risk factor for abortion in FET cycles, and controlling uric acid levels prior to conducting FET may decrease the abortion rate.

Objective:To investigate the influence of serum uric acid level on the pregnancy outcome of frozen-thawed embryo transfer (FET).Methods:This study was a retrospective cohort study. Patients were recruited underwent the first FET cycles at the Reproductive Medicine Center of Affiliated Hospital of Nantong University from January 2017 to June 2022. According to uric acid >340 μmol/L or not, the patients were divided into high uric acid group ( n=157) and control group ( n=899). Propensity score matching (PSM) and multivariate logistic regression analysis were conducted to screen the risk factors for adverse pregnancy outcomes. Results:Patients in high uric acid group had a higher proportion of overweight [60.5% (95/157)], higher level of anti-Müllerian hormone [4.59 (3.23, 6.32) μg/L] and antral follicle count [21 (15, 28)] compared with control group [13.2% (119/899), P<0.001; 4.46 (2.51, 5.27) μg/L, P=0.024; 19 (12, 25), P=0.003], and lower levels of basic follicle-stimulating hormone [(6.73±2.04) U/L] and estradiol on transformation day [232.97 (147.13, 358.40) pmol/L] compared with control group [(7.42±2.29) U/L, P<0.001; 285.80 (189.11, 393.52) pmol/L, P=0.001]. The abortion rate was higher [43.7% (38/87)] and the live birth rate was lower [31.2% (49/157)] in high uric acid group than in control group [23.6% (120/509), P<0.001; 43.3% (389/899), P=0.005]. After PSM, the abortion rate was significantly higher in high uric acid group as far [43.7% (38/87)] than in control group [23.0% (17/74), P=0.006], and high uric acid greatly increased the abortion rate in FET patients before and after PSM (before PSM: OR=2.193, 95% CI: 1.301-3.697, P=0.003; after PSM: OR=3.482, 95% CI: 1.620-7.483, P=0.001). Conclusion:High level of uric acid before the pregnancy is an important risk factor for abortion in FET cycles, and controlling uric acid levels prior to conducting FET may decrease the abortion rate.

Cleft lip and palate is a common congenital malformation, and its sequential treatment time is long and complicated. Many factors affect the treatment result . Operation is the main treatment for cleft palate. Its main goal is to close the abnormal defect to prevent disorders of speech development and eating, while ensuring the minimum impact on the growth of the maxilla. Cleft lip repair has been carried out for many years at home and abroad by using vomer bone flap to repair the hard palate at the same time, and a large number of research reports have been reported. This article reviews the effect of the treatment mode on the related anatomical structures of cleft lip repair with vomer bone flap repairing the hard palate, in order to explore the ideal treatment plan for cleft lip and palate.

Cleft lip and palate is a common congenital malformation, and its sequential treatment time is long and complicated. Many factors affect the treatment result . Operation is the main treatment for cleft palate. Its main goal is to close the abnormal defect to prevent disorders of speech development and eating, while ensuring the minimum impact on the growth of the maxilla. Cleft lip repair has been carried out for many years at home and abroad by using vomer bone flap to repair the hard palate at the same time, and a large number of research reports have been reported. This article reviews the effect of the treatment mode on the related anatomical structures of cleft lip repair with vomer bone flap repairing the hard palate, in order to explore the ideal treatment plan for cleft lip and palate.

Cleft lip and palate is a common congenital malformation, and its sequential treatment time is long and complicated. Many factors affect the treatment result . Operation is the main treatment for cleft palate. Its main goal is to close the abnormal defect to prevent disorders of speech development and eating, while ensuring the minimum impact on the growth of the maxilla. Cleft lip repair has been carried out for many years at home and abroad by using vomer bone flap to repair the hard palate at the same time, and a large number of research reports have been reported. This article reviews the effect of the treatment mode on the related anatomical structures of cleft lip repair with vomer bone flap repairing the hard palate, in order to explore the ideal treatment plan for cleft lip and palate.

Cleft lip and palate is a common congenital malformation, and its sequential treatment time is long and complicated. Many factors affect the treatment result . Operation is the main treatment for cleft palate. Its main goal is to close the abnormal defect to prevent disorders of speech development and eating, while ensuring the minimum impact on the growth of the maxilla. Cleft lip repair has been carried out for many years at home and abroad by using vomer bone flap to repair the hard palate at the same time, and a large number of research reports have been reported. This article reviews the effect of the treatment mode on the related anatomical structures of cleft lip repair with vomer bone flap repairing the hard palate, in order to explore the ideal treatment plan for cleft lip and palate.

Objective:To construct the evaluation index system of pediatric specialized nurses' core competence, so as to provide a basis for accurate measurement of pediatric specialized nurses' core competence.Methods:A research group was established in August 2021. Based on the quality onion model and literature analysis, a qualitative interview was conducted in September 2021 with 10 provincial and above hospitals pediatric specialist nurses, 5 pediatric nursing managers, 5 pediatric chief physicians and 5 primary caregivers for children selected by objective sampling. From September 2021 to February 2022, questionnaires were sent to 16 experts via email or WeChat for three rounds of Delphi expert consultation. The evaluation indexes of pediatric specialized nurses' core competence were determined according to the authority coefficient, Kendall coordination coefficient, coefficient of variation and other factors.Results:Among three rounds of expert consultation, the effective recovery rates of the questionnaire were all 100.00% (16/16) , and the authority coefficients were 0.813, 0.888 and 0.895, respectively, and the Kendall coordination coefficients were 0.175 (χ 2=289.348, P<0.01) , 0.239 (χ 2=408.131, P<0.01) and 0.288 (χ 2=467.280, P<0.01) , respectively. The final evaluation index system of pediatric specialized nurses' core competence included 6 first level indicators, 18 second level indicators and 84 third level indicators. Conclusions:The evaluation index system of pediatric specialized nurses' core competence is scientific and reliable, which can be used as an effective tool to measure the core competence of pediatric specialized nurses.

Objective:To analyze the epidemiological and clinical characteristics of patients with imported corona virus disease 2019 (COVID-19) in Beijing City.Methods:A case-control study was performed to retrospectively analyze 69 cases of imported COVID-19 from abroad and 147 cases of domestic confirmed COVID-19 from China as a control group from January 20 to March 20, 2020 admitted to Beijing Ditan Hospital, Capital Medical University.The epidemiological and clinical characteristics were compared.Statistical analysis were performed by t test, Mann-Whitney U test, chi-square test and Fisher exact test. Results:The main sources of the cases in the import group were from the United Kingdom, Italy, Spain and other European countries, with 44.9%(31/69) of the overseas students entering the country by air. The age of the imported group (27(21, 40) years) was lower than the domestic group (43 (32, 59)years), the difference between the two groups was statistically significant ( U=2 828.500, P<0.01). Compared with the domestic group, the proportion of cases with contact history of confirmed cases in the imported group was lower (30.4%(21/69) vs 68.0%(100/147)), the interval between onset and admission ≤seven days was higher (81.2%(56/69) vs 66.0%(97/147)), the proportion of cases with underlying diseases was lower (21.7%(15/69) vs 44.2%(65/147)). The differences between the two groups were all statistically significant ( χ2=26.935, 5.233 and 10.175, respectively, all P<0.05). The proportion of mild cases in the imported group was higher than that in the domestic group (42.0%(29/69) vs 10.9%(16/147)). Seventeen cases with olfactory abnormality and 12 cases with taste abnormality were found in the imported group, while no olfactory and taste abnormality was found in the domestic group. The proportions of fever, weakness, muscle soreness and dyspnea were all lower than those of the domestic group, the differences between the two groups were all statistically significant ( χ2=13.851, 8.118, 9.730 and 16.255, respectively, all P<0.01). The proportions of cases with decreased lymphocyte absolute numbers (37.7%(26/69) vs 67.3%(99/147)) and increased C reactive protein level (15.9%(11/69) vs 51.8%(72/139)) were both lower than the domestic group, and the differences between the two groups were both statistically significant ( χ2=18.015 and 24.722, respectively, both P<0.01). The proportions of cases with ground glass shadow and consolidation of chest computed tomography were lower than those of the domestic group and the differences between the two groups were all statistically significant ( χ2=11.961 and 5.099, respectively, all P<0.05). In terms of complications, the proportions of cases with acute respiratory distress syndrome and acute myocardial injury were lower (2.9%(2/69) vs 10.9%(16/147) and 4.3%(3/69) vs 14.0%(16/114), respectively), and there were statistically significant differences between the two groups ( χ2=4.017 and 4.335, respectively, both P<0.05). There were no cases received mechanical ventilation and extracorporeal membrane oxygenation in the imported group, and the proportions of patients received oxygen therapy and antibiotic treatment were significantly lower than those in the domestic group (13.0%(9/69) vs 26.5%(39/147) and 13.0%(9/69) vs 39.5%(58/147), respectively) and the differences between the two groups were statistically significant ( χ2=4.942 and 15.797, respectively, both P<0.05). Conclusions:The majority of imported COVID-19 cases are mainly from European countries, mostly young and middle-aged, and mostly mild and ordinary types.The symptoms of olfactory and taste abnormality are found for the first time.

Objective:To evaluate the therapeutic effects of Tolvaptan on refractory heart failure in patients aged 75 years and older.Methods:This was a randomized controlled trial.A total of 68 patients with refractory heart failure aged 75 years and older were divided into the control group(n=38)and the experimental group(n=30)by randomly generated numbers.Patients in the control group were given levosimendan and recombinant human brain natriuretic peptide intravenously plus routine treatments such as diuresis and electrolyte correction.In the experimental group, 30 patients were given a single dose of 15 mg Tolvaptan per day in addition to what was received by the control group.The effects on heart failure were compared between the two groups 1 week after treatment.Changes in rehospitalization rate, emergency intervention frequency and mortality rate were recorded after a 3-month follow-up.Results:Clinical symptoms of heart failure were alleviated in both the experimental and control groups after treatment.Improvements in 24-h urine volume, body weight and 6-minute walking distance were more significant in the experimental group than in the control group after treatment[(1 470.5±200.6)ml vs.(972.5±201.7)ml, (-6.4±2.1)kg vs.(-2.8±1.9)kg, (189.3±13.7)m vs.(151.3±12.5)m, P<0.05]. Changes in serum sodium levels and improvement of LVEF were greater and reduction of N-terminal B-type brain natriuretic peptide(NT-proBNP)levels was more significant in the experimental group than in the control group after treatment[(5.2±2.1)μmol/L vs.(-1.1±2.4)μmol/L, (10.1±4.1)% vs.(7.0±4.0)%, (-6 670±1 815.7)ng/L vs.(-5 025.3±1 876.7)ng/L, P<0.05]. There was no significant difference in the incidence of adverse reactions between the two groups( P>0.05). The experimental group had shorter hospital stays, while the rehospitalization rate, emergency intervention times and mortality had no significant difference between the two groups during the follow-up period( P>0.05). Conclusions:Addition of Tolvaptan to treatment can increase urine volume, improve cardiac function, correct hyponatremia and shorten the length of hospitalization in refractory heart failure patients aged 75 years and older with good safety and has no significant impact on renal function.